Fibrinolysin, Human

Summary

Fibrinolysin, Human (CHEMBL1201505) is an approved unknown (ATC B01AD05); indicated across 3 conditions including thrombotic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• ATC class: B01AD05
• Indications: 3 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201505
Name	Fibrinolysin, Human
Type	Unknown
Max phase	4
ATC	B01AD05

Also known as: Fibrinolisina (humana), Fibrinolysin, Fibrinolysin (human), Fibrinolysin human, human, Fibrinolysine (humaine), Plasmin, Plasmin (bos taurus), Plasmin (bovine), Plasmin (human), Plasmin bovine, Thrombolysin.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1/PHASE2	2
PHASE2	2
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00347646	PHASE1/PHASE2	TERMINATED	A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)
NCT00348439	PHASE2	TERMINATED	Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment
NCT01014975	PHASE1/PHASE2	COMPLETED	A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients
NCT01222117	PHASE2	COMPLETED	A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
NCT00418483	PHASE1	COMPLETED	A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion
NCT04218890	Not specified	UNKNOWN	TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).